Form 4: 2seventy bio Director Leschly Reports Shares Disposition Following Bristol-Myers Squibb Merger

Director Nick Leschly reports disposition of shares and derivative securities of 2seventy bio, Inc. following the merger with Bristol-Myers Squibb.

Summary

• Nick Leschly, a director of 2seventy bio, Inc., filed a Form 4 detailing changes in beneficial ownership of the company's securities on May 15, 2025.
• The filing reports the disposition of common stock and stock options due to the merger between 2seventy bio and Bristol-Myers Squibb Company, which became effective on May 13, 2025.
• The merger involved Bristol-Myers Squibb acquiring all outstanding shares of 2seventy bio for $5.00 per share in cash.
• Leschly disposed of 335,964 shares of common stock directly held.
• Leschly disposed of 897,642 shares of common stock directly held.
• Leschly disposed of 15,233 shares of common stock held by Nick Leschly 2001 Trust.
• Leschly disposed of 41,000 shares of common stock held by Nick Leschly Irrevocable GST Trust of 2019.
• Additionally, outstanding stock options with an exercise price less than $5.00 were cancelled and converted into the right to receive cash equal to the difference between the merger consideration and the exercise price.
• Stock options with an exercise price equal to or greater than $5.00 were cancelled for no consideration.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document primarily reports the completion of a merger and the resulting changes in ownership. It doesn't express positive or negative views, but rather provides factual information.

Future Outlook

The document does not contain any forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects a continuation of consolidation trends within the biotechnology industry, where larger pharmaceutical companies acquire smaller firms with promising technologies or drug candidates.

Comparison to Industry Standards

• Mergers and acquisitions in the biotech industry often involve a premium paid over the target company's existing share price.
• The $5.00 per share merger consideration should be compared to the trading price of TSVT prior to the announcement to assess the premium received by shareholders.
• Comparable transactions in the cell and gene therapy space, such as Gilead's acquisition of Kite Pharma, can provide benchmarks for valuation multiples and deal structures.

Key Dates

Keywords

Form 4, beneficial ownership, merger, 2seventy bio, Bristol-Myers Squibb, TSVT, Leschly, stock options, common stock, disposition